NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ('NNW'), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

纽约，2023年10月31日（GLOBE NEWSWIRE）-通过InvestorWire-Lexaria Bioscience Corp.（纳斯达克股票代码：LEXX）今天宣布其在NetworkNewsWire（'NNW'）发表的社论中的位置，该社论是60多个品牌之一动态品牌组合@IBN（InvestorBrandNetwork），一个专门的沟通平台，专注于私营和公共公司以及投资界的金融新闻和内容分发。

To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit: https://nnw.fm/q9osg   The prestigious “New England Journal of Medicine” recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes.

要查看完整的出版物，“糖尿病，减肥药能更好吗？”请访问：https://nnw.fm/q9osg着名的“新英格兰医学杂志”最近发表了一项针对2539名成年人的大型研究结果，其中体重减轻49至52磅是常见的结果。有超过3700万美国人患有糖尿病，并且在流行水平上患有肥胖症，毫不奇怪，数百万人正在称赞导致这些令人惊讶的积极结果的新一类药物。

GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. But there may be an even better avenue to increased effectiveness and better outcomes.

GLP-1激动剂是一类药物，主要帮助控制2型糖尿病患者的血糖（葡萄糖）水平，但也有助于治疗肥胖。似乎每个人都对控制血糖和轻松减肥感到兴奋。但可能有更好的途径来提高效率和更好的结果。

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.

Lexaria Bioscience Corp.（纳斯达克股票代码：LEXX）是药物输送平台的全球创新者，去年通过其DehydraTECH（TM）平台开始与糖尿病相关的正式研究，该平台显示血糖水平降低和体重减轻。有了这样令人鼓舞的早期结果，Lexaria计划开展新的人类和动物研究，以检查脱水处理是否可以使GLP-1药物如semaglutide更好。

About Lexaria Bioscience Corp. Lexaria’s patented drug-delivery technology.

关于Lexaria Bioscience Corp.Lexaria的专利药物输送技术。